A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

NCT02451930 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Stage IV Non-Small Cell Lung Cancer

Interventions

DRUG: Necitumumab
DRUG: Pembrolizumab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]